TJ Biopharma acquires Biogen's Greater China felzartamab rights
April 21, 2026 | 10:15
The Chinese pharmaceutical company secured licensing for the autoimmune disease antibody therapy covering mainland China, Hong Kong and Taiwan markets.
Mobile Version